A Phase I, Blinded Within Dose Groups, Multiple Dose, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Different Titration Schemes of BI 456906 in Patients With Obesity and Overweight
Phase of Trial: Phase I
Latest Information Update: 06 Sep 2019
Price : $35 *
At a glance
- Drugs BI 456906 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 03 Sep 2019 Planned End Date changed from 27 Jan 2020 to 4 May 2020.
- 03 Sep 2019 Planned primary completion date changed from 16 Dec 2019 to 20 Apr 2020.
- 31 Jul 2019 Planned number of patients changed from 130 to 117.